V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015775 | 160019107 | 0 | 81.6 | Curative (C) | 2020-07-16 | 2020-07-30 | NB HRNBL-1 COJEC Ind COURSE B | 01 | N | CAPECITABINE + CARBOPLATIN | 101406357 |
| 160015794 | 160019108 | 1.67 | 73.75 | null | 2019-10-29 | 2019-10-29 | PEMBROLIZUMAB | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 100547941 |
| 160015799 | 160019109 | 0 | 53 | null | 2018-09-18 | 2018-09-18 | EW EuroEwing 2012 Arm B VDC | 02 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 100988419 |
| 160015807 | 160019110 | 1.63 | 67.8 | null | 2019-10-04 | 2019-10-13 | EW EuroEwing 2012 Arm B IE | null | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100864853 |
| 160015809 | 160019111 | 0 | 112 | Palliative (P) | 2020-09-03 | 2020-09-03 | Cetuximab 14 day | 02 | N | PEMBROLIZUMAB | 100276551 |
| 160015810 | 160019112 | 1.65 | 70.05 | Palliative (P) | 2017-06-15 | 2017-07-31 | IVADo | 02 | N | NIRAPARIB | 101421285 |
| 160015822 | 160019113 | 1.46 | 54.9 | null | 2019-10-13 | 2019-10-14 | Olaratumab | 02 | null | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100161542 |
| 160015828 | 160019114 | null | 75 | Palliative (P) | 2019-11-28 | 2020-01-18 | null | 02 | N | TOPOTECAN | 101299042 |
| 160015833 | 160019115 | null | null | null | 2020-01-01 | 2020-01-28 | Rituximab | 02 | null | OLARATUMAB | 100956787 |
| 160015849 | 160019116 | 1.74 | 79 | null | 2022-04-04 | 2022-04-11 | Trial Unspecified | 02 | null | CONFIRM TRIAL | 101610665 |
| 160015851 | 160019117 | 1.56 | 80.2 | null | 2018-03-28 | 2018-04-16 | Cisplatin 7 day | 02 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101470115 |
| 160015859 | 160019118 | 1.57 | 67.8 | Palliative (P) | 2016-12-21 | 2017-05-22 | Bevacizumab+Carbo+Pacliaxel | 02 | N | ETOPOSIDE | 100282020 |
| 160015875 | 160019119 | 1.62 | 67 | null | 2021-01-29 | 2021-05-11 | Vincristine (weekly) | null | null | IRINOTECAN + CISPLATIN + MITOMYCIN | 100721031 |
| 160015880 | 160019120 | 1.73 | 108.35 | Curative (C) | 2021-04-24 | 2021-05-18 | Trial Unspecified | 02 | N | IFOSFAMIDE | 100669712 |
| 160015898 | 160019122 | 1.93 | 73 | Curative (C) | 2018-03-21 | 2018-03-21 | PEMBROLIZUMAB | 02 | N | EW EUROEWING 2012 ARM B IE | 100851443 |
| 160015916 | 160019124 | 1.52 | 78.9 | Neo-adjuvant (N) | 2017-08-13 | 2017-08-27 | IVA | 02 | N | VINCRISTINE | 101853045 |
| 160015943 | 160019126 | null | null | Palliative (P) | null | 2021-12-26 | DACTINOMYCIN + CYCLO + VINCRISTINE | 01 | N | PEMBROLIZUMAB | 101679938 |
| 160015951 | 160019127 | 1.5 | 13 | null | 2021-01-20 | 2021-06-25 | null | 02 | null | EW EUROEWING 2012 ARM B IE | 100041219 |
| 160015952 | 160019128 | null | 56 | null | 2019-08-19 | 2019-08-22 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100137761 |
| 160015953 | 160019129 | 1.57 | 93 | null | 2016-08-13 | 2016-11-17 | Gemcitabine day 1&8 | null | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100409884 |
| 160015969 | 160019130 | 1.65 | 70.1 | Palliative (P) | 2018-05-22 | 2018-08-16 | Etoposide oral | 02 | N | IVA | 101127652 |
| 160015971 | 160019131 | 0 | 81.6 | null | 2018-07-20 | 2018-07-22 | Carboplatin + Vinorelbine IV | null | null | IRINOTECAN + TEMOZOLOMIDE | 101396540 |
| 160015973 | 160019132 | null | 17.6 | Curative (C) | 2018-11-07 | 2019-09-28 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | Y | ABIRATERONE | 100533153 |
| 160015996 | 160019133 | 1.76 | 63.9 | Palliative (P) | 2019-12-05 | 2020-01-07 | null | 02 | N | RUCAPARIB | 100967871 |
| 160016007 | 160019134 | 1.73 | 77 | Curative (C) | 2016-06-27 | 2016-06-27 | Niraparib | 1 | N | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 100885300 |
| 160016038 | 160019135 | 1.69 | 76.6 | Curative (C) | 2019-07-16 | 2019-08-10 | Trial Unspecified | 01 | N | IMATINIB | 101849043 |
| 160016059 | 160019137 | 0 | 72.6 | null | 2017-03-05 | 2017-03-17 | Cyclophosphamide oral | 01 | null | NIRAPARIB | 101423964 |
| 160016071 | 160019138 | 0 | 90.6 | Curative (C) | 2019-10-29 | 2019-11-05 | Rituximab | 02 | null | TRIAL | 101610285 |
| 160016102 | 160019139 | 1.74 | null | null | 2020-05-20 | 2020-05-20 | EW EuroEwing 2012 Arm B VC | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 100224260 |
| 160016118 | 160019140 | 1.74 | 49.95 | Neo-adjuvant (N) | 2020-06-26 | 2020-07-18 | GEMCITABINE | 02 | Y | ETOP 13-18 BEAT-MESO TRIAL | 101008628 |
| 160016122 | 160019141 | 0 | 10.5 | null | 2019-07-07 | 2019-07-07 | TOPOTECAN | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100365512 |
| 160016128 | 160019142 | 0 | 15.3 | 03 | 2020-07-07 | 2020-08-21 | VINCRISTINE | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101536348 |
| 160016143 | 160019143 | 1.59 | 24.2 | Palliative (P) | null | 2018-07-02 | NB HRNBL-1 Isotretinoin | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101844682 |
| 160016154 | 160019144 | 1.76 | 48.4 | Curative (C) | 2019-09-06 | 2019-09-26 | EW EuroEwing 2012 Arm A/B BuMEL | 02 | N | NB HRNBL-1 COJEC IND COURSE A | 100806339 |
| 160016155 | 160019145 | 1.6 | 84.5 | Palliative (P) | null | 2020-11-11 | null | 02 | null | DARATUMUMAB | 100008589 |
| 160016172 | 160019147 | 0 | 94 | Palliative (P) | 2016-10-13 | 2016-10-14 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | N | VINCRISTINE | 101857592 |
| 160016183 | 160019148 | 1.62 | 12 | Palliative (P) | 2018-01-22 | 2018-02-14 | EW EuroEwing 2012 Arm B IE | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 100705666 |
| 160016208 | 160019149 | 1.7 | 36.5 | Palliative (P) | 2020-12-22 | 2021-05-02 | Ifosfamide | 02 | N | NB HRNBL-1 COJEC IND COURSE C | 101453452 |
| 160016209 | 160019150 | 1.72 | 65 | Curative (C) | 2021-11-11 | 2021-11-11 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | DACARBAZINE | 100261378 |
| 160016215 | 160019151 | 1.71 | 18 | Curative (C) | 2018-06-22 | 2018-07-18 | Ifosfamide | 02 | null | MELPHALAN + TREOSULPHAN | 101711099 |
| 160016227 | 160019153 | 1.7 | 77.9 | null | 2018-11-27 | 2018-11-27 | null | 01 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100301185 |
| 160016234 | 160019154 | 1.82 | 88.5 | null | 2018-06-24 | 2018-11-17 | VIDE | 02 | null | CYCLOPHOSPHAMIDE | 101787831 |
| 160016264 | 160019155 | 1.63 | 80.5 | Palliative (P) | 2016-12-07 | 2016-12-12 | DACARBAZINE + GEMCITABINE | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 100463884 |
| 160016279 | 160019156 | 0 | 53.8 | Curative (C) | 2021-12-31 | 2022-01-22 | IVA | 02 | N | RMS VDCE | 100874490 |
| 160016287 | 160019157 | 1.65 | 11.3 | Palliative (P) | 2018-10-04 | 2018-10-06 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | STS NON-RHABDO EPSSG 2005 | 101210219 |
| 160016291 | 160019158 | 1.56 | 116 | null | 2016-12-06 | 2018-07-04 | NB HRNBL-1 COJEC Ind COURSE B | null | null | EW EUROEWING 2012 ARM B VC | 100344862 |
| 160016304 | 160019159 | 1.6 | 67.4 | null | 2018-02-28 | 2018-05-30 | CVP R | 02 | null | STS NON-RHABDO EPSSG 2005 IVA | 100017071 |
| 160016308 | 160019160 | 1.7 | 18.5 | Palliative (P) | 2019-05-18 | 2019-06-09 | VAI (Ifos 3g/m2) | 02 | N | REGORAFENIB | 101681747 |
| 160016323 | 160019161 | 1.65 | 66 | Curative (C) | 2021-01-27 | 2021-03-02 | Dacarbazine | 02 | N | GEMCITABINE | 101402071 |
| 160016342 | 160019162 | 1.56 | 81 | null | 2020-04-26 | 2020-05-09 | Cisplatin + Liposomal Doxorubicin | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100428007 |